<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911897</url>
  </required_header>
  <id_info>
    <org_study_id>CRD0120</org_study_id>
    <nct_id>NCT01911897</nct_id>
  </id_info>
  <brief_title>Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)</brief_title>
  <acronym>CALM-FIM_EUR</acronym>
  <official_title>CALM-FIM_EUR - Controlling and Lowering Blood Pressure With the MobiusHD - A Prospective Multicenter Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Dynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Dynamics, Inc.</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the MobiusHD system in subjects with resistant
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe.
      Eligible subjects with stage 2 resistant systemic arterial hypertension currently being
      treate4d with a minimum of three (3) anti-hypertensive drugs, who consent to study
      participation will be assigned to treatment with the MobiusHD system.

      Potential study participants will be consented and then screened at two (2) baseline visits
      beginning at least 30 days prior to MobiusHD placement.  Qualified patients will undergo
      placement of the MobiusHD under angiographic visualization, and will then be followed for 36
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six(6) months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decrease in office cuff blood pressure (BP).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>MobiusHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MobiusHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MobiusHD</intervention_name>
    <description>Implant that is placed in the carotid sinus to control hypertension.</description>
    <arm_group_label>MobiusHD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following
             at least one (1) month of maximally tolerated therapy with at least three (3)
             anti-hypertensive medications, of which at least one (1) must be a diuretic unless
             patient has history of intolerance, ineffectiveness or contraindications.  Any
             combination medications will be counted per the active ingredient (for example,
             Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)

        Exclusion Criteria:

          -  Known or clinically suspected baroreflex failure or autonomic neuropathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Van der Heyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sujith J Shetty, MBBS</last_name>
    <phone>01-650-963-9370</phone>
    <email>sshetty@vasculardynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Peeters</last_name>
      <phone>0032 (0)89327193</phone>
      <email>nele.peeters@zol.be</email>
    </contact>
    <investigator>
      <last_name>Jo Dens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Rost</last_name>
      <phone>+31 (0)30 609 22 78</phone>
      <email>i.rost@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Van der Heyden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart V. Coenen</last_name>
      <phone>(+31) 613274143</phone>
      <email>B.vanCoenen@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Lukas van Dijk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
